علاج التشوه الشرياني الوريدي الدماغي في التشوه الشرياني الوريدي الدماغي غير المتشقق

References

• The optimal approach to management of unruptured bAVMs remains a subject of debate because of insufficient high-quality, consistent evidence about the lifetime risks of ICH and its predictors and the complications associated with treatment.
• Only 1 randomized controlled trial exists to inform the management of unruptured bAVMs: ARUBA.
• Current treatment options include conservative management, surgical resection, stereotactic radiosurgery (SRS), endovascular embolization, or combinations of these treatments (multimodal therapy).
• The definitive treatment of bAVMs should be complete elimination of the nidus and the arteriovenous shunt.
• Most studies show bAVM obliteration in 70% to 80% of bAVMs, and obliteration is typically achieved within 2 to 3 years after treatment.